Could dopaminergic drugs help people whose depression doesn't respond to standard antidepressants?
Approximately one third of people with depression do not respond to serotonin-based antidepressants — a phenomenon known as treatment-resistant depression. According to Dr. Masud Husain, clinical trials are now actively exploring whether these patients respond instead to dopaminergic medications, the same class of drugs used to treat apathy. His reasoning: some depressed patients may have an overlapping apathy component that serotonergic drugs simply do not address.
This distinction matters clinically. Husain draws a clear line between pure depression, pure apathy, and mixed presentations where both conditions coexist. A patient who appears depressed but whose real underlying problem involves blunted motivation — a dopamine-related deficit rather than a serotonin-related one — will not improve on a selective serotonin reuptake inhibitor. Targeting the wrong neurotransmitter system leaves a significant share of patients without relief.
Clinical distinction
Husain identifies three separate presentations: pure depression (primarily a serotonin system issue), pure apathy (primarily a dopamine/motivation system issue), and mixed presentations where both are present. Treatment resistance in depression may, in part, reflect undetected apathy that requires a dopaminergic rather than serotonergic approach.
The evidence that dopaminergic drugs can reverse motivational deficits is not theoretical. In the episode, Husain describes a patient whose severe apathy — following strokes deep in the basal ganglia — was completely reversed by Ropinirole, a drug that acts on dopamine receptors. That case illustrates, in compelling clinical terms, what happens when the dopamine motivation system is directly targeted. Whether the same mechanism explains a subset of treatment-resistant depression is what current trials are now testing. You can hear Husain lay out the full argument in his conversation with Jennifer Cohen on Habits and Hustle on Listenly.
"For David, the effort of putting the music systems together was not worth the reward of being able to listen to something pleasurable — and in David's case, very few things were worth the effort."
— Masud Husain, Habits and Hustle, Episode 579That description of David — unable to find any action worth the effort it demanded — maps directly onto what Husain suspects is happening in a subset of depressed patients. They are not simply sad; their cost-benefit calculus for effort is broken. For those patients, a drug that rebalances dopaminergic signaling, rather than one that raises serotonin, may be the more appropriate intervention.
About Masud Husain
Masud Husain is widely recognized as one of the world's leading neurologists in the study of memory, motivation, and cognitive decline. He co-leads the Dementia Research Group at Oxford University — the same institution where he was educated — and serves as editor-in-chief of Brain, one of the most prestigious and rigorously peer-reviewed journals in the field of neurology. His scientific authority is not built on theory alone: Husain has spent decades working directly with patients, studying the real-world consequences of neurological damage to understand what actually governs how people think, act, and maintain cognitive sharpness as they age. It is this patient-first approach that gives his clinical observations on treatment-resistant depression and dopaminergic drugs particular weight — his insights emerge from treating and observing real cases, including patients whose profound motivational failures turned out to be both diagnosable and reversible with the right pharmacological target.
See also
Can apathy caused by brain damage be treated with medication, and what is the evidence?
Dr. Husain treated his patient David with Ropinirole, a drug that works on dopamine receptors in the brain, after David's strokes caused severe apathy. Within three months, David had returned transformed — with a new job and a new girlfriend — providing compelling real-world evidence that dopaminergic treatment can reverse apathy caused by neurological damage.
Is there any scientific evidence that social media scrolling causes dopamine hits?
Dr. Husain states there is absolutely no evidence that scrolling through social media produces dopamine hits, calling it a myth perpetuated in part by popular culture and misapplied neuroscience.
What does dopamine actually do in the brain, and is it really the "pleasure chemical"?
Dr. Husain explicitly debunks the idea that dopamine is the pleasure chemical, stating that both animal and human evidence contradicts this. Dopamine's real role is in motivation and the drive to pursue rewards, not in the experience of pleasure itself.